Explore News By Topic
10/22/2019
Results of the CARD trial: Benefit for patients needing a third-line therapy option
Metastatic castration-resistant prostate cancer (mCRPC) refers to prostate cancer that has spread outside the prostate and no longer responds to traditional androgen deprivation therapy (ADT). Patients have several different treatment options, including second-generation androgen-signaling-targeted inhibitors (ARTA) like abiraterone or enzalutamide, and chemotherapy drugs (docetaxel, cabazitaxel). However, for patients whose disease... Read More
10/15/2019
Artificial Intelligence and Prostate Cancer Diagnosis
The field of artificial intelligence (AI) started in the 1950’s in the defense industry, and has evolved over the years. In the 2010s, new computer-based “deep-learning” methods were introduced that significantly accelerated the field. Physician-scientists are using this technology in the medical field to improve diagnostic methods. One such researcher... Read More
10/01/2019
Studying the Effects of ADT on Brain Function
Androgen deprivation therapy (ADT) is a primary treatment for prostate cancer, and acts by blocking the production or action of testosterone and other male hormones that activate the androgen receptor (AR). Studies have suggested that ADT may affect cognition and has been associated with the development of Alzheimer’s disease and... Read More
10/01/2019
New Precision Medicine Treatment Could Benefit Many Men with Treatment-Resistant Metastatic Prostate Cancer
October 1, 2019. A study presented yesterday at the 2019 European Society for Medical Oncology (ESMO) Congress reported positive results from a Phase 3 clinical trial testing the PARP-inhibitor olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer (mCRPC) who have alterations in certain DNA damage repair (DDR) genes; a... Read More
09/26/2019
THE PROSTATE CANCER FOUNDATION ANNOUNCES A COLLABORATIVE GRANTS PROGRAM IN PROSTATE CANCER RESEARCH
LOS ANGELES, Calif., September 26, 2019 – The Prostate Cancer Foundation (PCF) today announced a collaboration with Pfizer Global Medical Grants to fund approximately $2 million in research grants through a Competitive Research Grants Program, which is focused on investigating talazoparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in prostate cancer.... Read More
09/18/2019
FDA Approves Apalutamide (Erleada) for the treatment of metastatic hormone-sensitive prostate cancer
September 18, 2019 – Last night the U.S. Food and Drug Administration (FDA) approved apalutamide (Erleada) for the treatment of metastatic hormone-sensitive (aka, “castration-sensitive”) prostate cancer (mHSPC). Apalutamide has previously received FDA-approval for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC). PCF funded the initial synthesis of apalutamide at UCLA... Read More
09/04/2019
The Prostate Cancer Foundation Made History by Lighting U.S. Landmarks “Blue” Across All 50 States to Illuminate Prostate Cancer Issue
LOS ANGELES, Calif., September 4, 2019 – For the first time in American history, U.S. landmarks in all 50 states (and the District of Columbia) were lit blue on September 3 to kick-off Prostate Cancer Awareness Month. The Prostate Cancer Foundation’s (PCF) “Light It Blue” campaign is a national effort... Read More
08/22/2019
The Prostate Cancer Foundation and the Movember Foundation Announce 2019 Challenge Award Winners
The Prostate Cancer Foundation (PCF) and the Movember Foundation today announced three new Movember Foundation-PCF Challenge Awards. These are granted to teams at some of the world’s leading cancer research institutions. They will receive a total of $2.5 million to support cross-disciplinary pioneering research toward the goal of finding a... Read More
07/30/2019
FDA Approves Bayer’s Nubeqa® (darolutamide), a New Treatment for Men with Non-Metastatic Castration-Resistant Prostate Cancer
WHIPPANY, N.J., July 30, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today approved Nubeqa® (darolutamide), an androgen receptor inhibitor (ARi), for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC). The FDA approval is based on the Phase III ARAMIS trial evaluating Nubeqa plus androgen deprivation... Read More
07/23/2019
Gene test picks out prostate cancer patients who could benefit from ‘search-and-destroy’ medicine
Original Press Release Issued by: The Institute of Cancer Research, London Testing for genetic weaknesses in repairing DNA could pick out men who may benefit from a new type of targeted nuclear medicine, a new study reports. An emerging class of drugs are made up of a radioactive particle that... Read More